New Research Estimates Cytokine-Based Drug Sales Account for Roughly 20% of the World Biopharmaceutical Market.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c49692) has announced the addition of "Current Drug Development Market for Cytokines Cytokines Chemicals made by the cells that act on other cells to stimulate or inhibit their function. Cytokines that stimulate growth are called "growth factors. , Chemokines and Growth Factors" to their offering. "Current Drug Development Market for Cytokines, Chemokines and Growth Factors" focuses primarily on the cytokine Cytokine Any of a group of soluble proteins that are released by a cell to send messages which are delivered to the same cell (autocrine), an adjacent cell (paracrine), or a distant cell (endocrine). market, company pipelines and trials in the field of cytokine research. This report succinctly suc·cinct adj. suc·cinct·er, suc·cinct·est 1. Characterized by clear, precise expression in few words; concise and terse: a succinct reply; a succinct style. 2. details all the latest advances in the push to market of cytokine-based therapeutics: which products have evolved, which have failed and new players on the field. Primary readers will have comprehensive updates on relevant company pipelines. Unique to this report is the comprehensive nature of compiled biological response modifiers biological response modifiers, n.pl substances such as phytochemicals and fibers that modulate mech-anisms related to the development of disease, such as hormonal changes, immune function, inflammatory activity, oxidative stress, and home-ostasis. currently in clinical testing. From the many interleukins to the vast array of growth factors, most all currently developed monoclonals, diabodies, soluble receptors, vaccines, small molecule antagonists antagonists, n muscles that counterbalance agonists during specific movements. opioid Neurology A pain-attenuating peptide that occurs naturally in the brain, which induces analgesia by mimicking endogenous opioids at opioid , peptide mimetics, recombinantly altered antigens, as well as RNA interference RNA interference n. A process in which the introduction of double-stranded RNA into a cell inhibits the expression of genes. and gene therapy vectors and plasmids are covered. Also unique is the easy reference tables provided for "at-a-glance" assessment of developmental pipeline progress. Market projection * The authors estimate that 2008 biopharma sales statistics covering cytokines will be in the range of: * Total world market, in terms of corporate revenues from biopharmaceutical sales, is probably about $80 - 100 billion * The largest portion of sales, of about 50 - 60% involves recombinant proteins Since human recombinants have replaced the animal version in human therapeutics, the prefix of "rh" for "human recombinant" appears less and less in the literature Human recombinants that replaced animal or harvested from human types * Other major sectors in terms of sales Terms of sale Conditions under which a firm proposes to sell its goods or services for cash or credit. are vaccines ($15 billion), and human plasma-derived proteins (~$10 billion), with all other biopharmaceuticals accounting for $10 or more billion in sales * There could well be another $5 billion in sales of miscellaneous biosimilars, as older cytokine recombinant patents expire * Overall, cytokine-based drug sales seem to account for ~20% of the world biopharmaceutical market Report Benefits * Identify which companies continue to leverage cytokine-based drugs and which companies license off developed cytokine technologies * Examine details on which small biotech start-up R&D pipelines are seeking big pharma development on a cytokine to cytokine basis * Explore products that continue to advance in the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval cycle, seeking expanded label-uses * Research novel and newly discovered cytokine applications and pathways, which are highlighted to facilitate future drug discovery. Start-up ventures are given a firm footing in the vast landscape of cytokine drug discovery and development and big pharma will be informed as to which of the many small biotech companies may meet their partnering or acquisition needs. Companies mentioned: - Anacor Pharmaceuticals - Angiogenix - Antisense Pharma - BioMimetic - Biopharm GmbH - BioVex - Cantabria - Domantis - ESBATech - Nautilus Biotech - Neovacs - Pivotal BioSciences - Renovo - Scil Technology - Uriach - Vaccinex - Xencor - Yes Biotech For more information visit http://www.researchandmarkets.com/reports/c49692 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion